Objective. To evaluate in vitro the potential links between sialyl Lewis X (sLeX) and cancer stem cells (CSC) in head and neck squamous cell carcinoma (HNSCC). HNSCC is an aggressive malignancy with high mortality mainly due to metastasis. CSC have emerged as important players in HNSCC metastasis. sLeX is a tetrasaccharide carbohydrate known to play a key role in metastatic dissemination by promoting binding of the tumor cells to the endothelium.
Introduction
The mortality associated with head and neck squamous cell carcinoma is still unacceptably high and it remains among the highest of the major solid cancers. 1 Despite improvements in the local control of head and neck squamous cell carcinoma (HNSCC), many patients continue to die from this disease due to the development of distant metastases. 2 The oral, head, and neck cancer 5-year survival rate is a dismal 17% for patients with distant metastases, compared to over 80% for those with localized disease. 2 Novel prognostic tools and therapeutic approaches are greatly needed.
The identification of cancer stem cells (CSC), the highly tumorigenic subpopulation of cells in human cancers, has created a new area of research with promising applications in the prognosis and therapeutics of cancer. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Characterizing CSC cancer subpopulations in HNSCC will lead to a better understanding of cancer recurrence, metastasis, and resistance to treatment and should pave the way for more effective therapies for HNSCC. Work by Prince et al 3 in 2007 was the first to identify CSC in HNSCC using the cellular marker CD44 and flow cytometry. These cells possessed the qualities of self-renewal, tumorigenesis, and the ability to recapitulate a heterogeneous tumor. 3 We have previously designed both in vitro and in vivo models of HNSCC metastasis to study the behavior of this unique tumor cell subpopulation, the CSC, and our data have shown that CSC possess a greater capacity for tumor growth, increased mobility, and invasive characteristics. Our in vivo experiments have confirmed the greater metastatic potential of CSC compared to non-CSC, 13 suggesting that CSC may be responsible for the development of HNSCC metastasis. Clinically, CSC enrichment has been found enhanced in recurrent disease, treatment failure, and metastasis (reviewed in Chinn et al 14 ) . However, it remains unclear how HNSCC CSC carry out the metastatic process.
Metastatic dissemination is directly related to the binding of cancer cells to endothelial cells (EC) through preferential expression of EC ligands. [15] [16] [17] [18] Our preliminary studies indicated that sialyl Lewis X (sLeX), a glycan that binds with strong affinity to the E-selectin, facilitates HNSCC binding to EC under conditions of flow. 19, 20 Expression of sLeX has been observed in several human malignancies, including HNSCC, and circulating levels of sLeX positive tumor cells were reported to be predictive for metastasis in various gastrointestinal carcinomas. [15] [16] [17] [18] 21, 22 Therefore, we postulated that CSC preferentially express the endothelial adhesion molecules ligand, sLeX, that may increase their ability to adhere to the lining of blood vessels and thereby to form metastasis. In the current study, we examine the level of expression of sLeX in a panel of HNSCC cell lines established at the University of Michigan (UMSCC 10A, 10B, 11A, 11B, 22A, 22B, 12, 6, 103, 14A, 14B, 47; 23 see Table 1 in the publication by Carey 23 ); UMSCC 103 cell line was freshly isolated from a very aggressive HNSCC primary oral carcinoma resistant to treatment with poor clinical outcome (manuscript under review). We assessed the expression profile of sLeX both as membrane-bound and secreted soluble forms. Our goal was to investigate the potential links between sLeX and CSC in HNSCC and to determine its relationship with the CD44 and aldehyde dehydrogenase (ALDH) status. Our findings provide the first evidence of sLeX implications in CSC in head and neck carcinomas and extend our previous studies on the molecular characterization of CSC in HNSCC.
Materials and Methods

Cell Lines and Culture of Adherent Cells
All cell lines used were established at the University of Michigan under a protocol approved by the Institutional Review Board Office in accordance with the university's regulations; 23 their characteristics are illustrated in Table 1 . They were cultured in Dulbecco's Modified Eagle Medium, 1% nonessential amino acids, 100X (Invitrogen), 1% Penicillin-Streptomycin, 100X (Invitrogen, Carlsbad, California). The cell lines tested negative in periodic monitoring for mycoplasma. The cell lines were genotyped to rule out crosscontamination and to confirm their identity, and their morphology was regularly examined. Human normal oral keratinocytes (NOK) were used as control and were grown in basal keratinocyte growth media (KGM) supplemented with hydrocortisone, insulin (bovine), human epithelial growth factor (EGF), and bovine pituitary extract, in accordance with the manufacturer's instructions (Lonza, Walkerswille, Maryland).
Supernatant Collection
We have previously found that the expression profile of various tumor-promoting cytokines secreted by HNSCC at varying time periods (4, 8, 24, 48, and 72 hours) are indicative of their metastatic potential. 24 Supernatants were collected in each of these time points as previously described 24 and analyzed for the sLeX expression by Western blot. Protease inhibitors (Complete Mini Kit with EDTA, Roche, San Francisco, California) were added to the supernatants, which were then processed in accordance with the manufacturer's instructions.
Orospheres Culture
Tumor cells were plated (60,000 cells/well) in 6-well ultralow attachment plates (Corning Inc., Corning, New York) in DMEM/F12 medium with supplements (N2, B7, human EGF, and beta-Fibroblast Growth Factor, FGF; 20ng/ml; Sigma) as we have previously described. 25, 26 Aldehyde Dehydrogenase Assay
We used the nonimmunologic enzymatic ALDEFLUOR TM Kit (STEMCELL Technologies Inc, Vancouver, Canada) as previously reported. 27 Fluorescence Activated Cell Sorting (FACS)
FACS was employed to characterize sLeX and CD44 protein expression levels as previously described. 13 , which was 100% sLeX1 as positive control. 28 Viable cells were assessed by DAPI exclusion and gated for forward and orthogonal light scatter with filters appropriate for the fluorescent antibody tag.
Immunofluorescence (ICF) and Immunocytochemistry (ICH)
ICF and ICH were performed as we have previously described. [29] [30] [31] Cells were grown in slide chambers (BD), then fixed with 4% formalin for 30 minutes on ice. Image FX TM enhancer (InVitrogen) was used prior to blocking. Freshly prepared paraffin-embedded sections from the corresponding primary tumors (HN-111) used for the derivation of the UMSCC-103 were stained for sLeX. Images were obtained on a Nikon scope equipped with an Olympus camera and processed on Olympus DSP Image Manager.
Western Blot
Proteins from HNSCC supernatants or total cell lysates were extracted in RIPA buffer, 1% SDS and loaded on 4% to 12% Tris Novex (Life Technologies, Grant Island, New York) and run as previously described. [29] [30] [31] Western blot was carried out with the same sLeX antibody (incubation in PBS-0.1% Tween with 5% milk, at 37 o C for 1 hr), then with the secondary (anti-mouse HRP) for 30 minutes. Development was done with SuperSignal West Pico System (Thermo Scientific, Rockford, Illinois).
Statistical Analysis
Values for repeats have been averaged and standard deviations have been calculated. We have used two-tailed t test to compute the exact probability (P) values; \.05 were considered significant.
Results sLeX Expression in HNSCC Grown as Adherent Cells
Our FACS analysis ( Figure 1) indicates that among the various head and neck sites, oral-derived HNSCC expressed highest sLeX, also showing an increasing tendency in cases that developed metastasis (UMSCC-103) or recurrences (UMSCC-14B). In contrast, NOK do not express sLeX (not shown). Figure 1 indicates the percentage of the cell population with sLeX expression as detected by flow cytometry. Secreted sLeX expression is also higher in oral carcinomas and it increases over the analyzed 72-hour time course (Figure 2 ; illustrated are UMSCC-103, -14A, and -14B cell lines whose sLeX levels of expression were among the highest as detected by flow cytometry). Overall, these data reveal that sLeX expression is predominant in oral-derived HNSCC, with increasing tendency with metastasis and recurrence.
sLeX Expression in HNSCC Grown as Orospheres sLeX expression was also analyzed by FACS using HNSCC cell lines grown in standard adherent condition (''adherent cells'') and grown as floating spheres (''orospheres'') in ultralow attachment plates (a condition that favors CSC The threshold for expression was defined by staining with an isotype control antibody. Our data indicate that sLeX is predominantly expressed in oral-derived carcinomas, showing an increasing tendency in cases that developed metastasis or recurrences.
growth). 25, 26, 32 Interestingly, HNSCC cell lines grown as orospheres were 93% to 100% positive for sLeX compared to 10% to 40% of the adherent counterparts, and their sLeX content increases with each passage (Figure 3) . The differences between orospheres and adherent counterparts were statistically significant for all the cell lines analyzed (UMSCC-14A, -14B, and 103: P = .013, P = .001, and P = .002, respectively); in contrast, the differences between -14B and -14A
were not. After cell sorting, both sLeX1 and sLeX-cells were able to form orospheres (Figure 4) . However, sLeX1 cells formed larger and more defined spheres. Of particular interest were the orospheres derived from sLeX-cells, which become 100% sLeX1 after 48 to 72 hours in culture, suggesting sLeX expression is a key characteristic of HNSCC CSC.
sLeX Relationship with CD44 and ALDH, the Traditional Stem Cells Markers in HNSCC 3, 13 We previously reported the CD44 expression levels as detected by flow cytometry in the UMSCC-6, -10A, -10B, -12, -14A, -14B, -47, and -103 (see Figure 2 in Davis et al 13 ).
The 10% to 15% of cells with the highest CD44 expression were collected as CD44 high , while the 10% to 15% with the lowest or no expression were collected as CD44 low cells. 13 We extended this analysis here by quantifying the cell populations with CD44 expression in the remaining lines from our panel: UMSCC-11A (9.59%) and -11B (83.16%). The U937 (100% sLeX1) expressed 48.65% CD44 high . We then assessed by flow the levels of co-expression for sLeX and CD44 cells, sorting the double positive cells, and found that metastatic and recurrent HNSCC, irrespective of primary site, exhibit higher percentage of sLeX/CD44 positivity. Interestingly, the highest percentage of double positive cell population is expressed by oral carcinoma cell lines, which either developed distant metastasis (UMSCC-103, a stage IV OSCC, patient survival time 10 months; 15.4%) or have recurred (UMSCC-14B, 7.5%) posttreatment failure. They are followed by UMSCC-11B, a stage IV larynx carcinoma refractory to chemotherapy that develop recurrence (patient survival time 14 months): 7.27%; the paired UMSCC-10: derived from a patient with a stage III larynx carcinoma that developed lymphnodes metastasis and had a survival time of 22 months (-10A: 7.08%; -10B: 6.57%); UMSCC-47, an oral carcinoma that initially presented with lymphnode involvement (T3N1M0): 4.82%; UMSCC-22B, a larynx lymphnode metastasis (patient survival time 22 months): 2.55% and its corresponding primary, UMSCC-22A: 1.17%. Our immunocytochemistry analysis identifies high sLeX levels in cells freshly cultured from a highly aggressive oral cancer resistant to standard treatment (UMSCC-103 and its corresponding primary, HN-111; Figure  5A -B), as well as the sLeX/CD44 co-expression ( Figure 5C ). Taken together, these findings suggest that sLeX may contribute to identifying the metastatic CSC cell subpopulations in conjunction with CD44 in HNSCC cell lines. Next, we extended our analysis to another molecule identified by our group as a marker for the head and neck CSC, the ALDH. 25 Given that the highest percentage of sLeX1 or double positive sLeX1/CD441 cells is expressed by oral-derived HNSCC, we focus our subsequent analysis on oral carcinomas cell lines, particularly 1 that developed distant metastasis (UMSCC-103, 8% ALDH1), 1 recurrence (UMSCC-14B, 6.3% ALDH1), and 1 that presented with locoregional (lymph nodes) metastasis (UMSCC-47, 31% ALDH1). Of interest, the percentage of ALDH1 cells significantly increases in sLeX1 sorted cells than in sLeX-or Figure 3 . Sialyl Lewis X (sLeX) expression in orospheres versus adherent oral carcinoma cells. Orospheres express higher sLeX than adherent cells (blue; corresponding isotype control, red); its expression increases with each passage (first: 93.1%, green; second: 97.2%, orange). unsorted cell subpopulations ( Figure 5D) . These preliminary findings show promise for the potential of sLeX in identifying CSC, particularly the ones from more aggressive HNSCC prone to metastasize or recur; additional studies are underway to further confirm these findings.
Discussion
Each year, over 400,000 new cases of HNSCC are diagnosed and more than 200,000 deaths are reported worldwide. 1 The main determinant of the HNSCC poor clinical outcome is the development of distant metastases. 2 Among the various sites of HNSCC, the oral-derived carcinomas remain the most aggressive and metastatic, with the poorest outcome. 1, 2 Cancer stem cells are defined as the small subpopulation of tumor cells that have distinctive biologic markers, exhibit self-renewal, and demonstrate the ability to generate new primary tumors and recreate the original tumor heterogeneity in immune deficient mice. [33] [34] [35] [36] [37] The highly tumorigenic properties of the CSC suggest that they may be the critical population of cancer cells in the development of metastasis, just as they have been proven to be in primary tumor development and growth. 13 Clinically, CSC enrichment is directly linked to tumor recurrence, treatment failure, and metastases in HNSCC (reviewed in Chinn et al 14 ) . The role of CSC in the development of metastasis is not yet well understood.
Recently, Prince and colleagues provided the first evidence of CSC in HNSCC based on the overexpression of the cellular marker CD44 expression. 3 We have since evaluated the metastatic potential of HNSCC CD441 CSC using a panel of well-characterized HNSCC cell lines generated at the University of Michigan and determined that CD441 expression by CSC correlates with the HNSCC in vitro invasive propensity and their ability to generate metastasis in vivo. 13 Data from other types of carcinomas have indicated that the tumor cells' ability to metastasize may depend on their expression levels of sLeX, a carbohydrate antigen that promotes the attachment of the tumor cells to the endothelium, a critical initial step that leads to metastatic dissemination. 15, [38] [39] [40] Based on our previous work indicating that sLeX1 HNSCC cells can bind to endothelium under conditions of flow, 19, 20 we hypothesized that sLeX expression by HNSCC facilitates cancer cell invasion and metastasis.
Emerging recent studies at the University of Michigan have identified CD44 and ALDH as a CSC markers in HNSCC. 13, 27, 32, 41, 42 Our current data indicate that tumor cells grown as orospheres (a condition that favors CSC growth) were highly positive for sLeX compared to their adherent counterpart; even the orospheres generated with sLeX-sorted cells became 100% sLeX1 within days. Floating orospheres were also strongly positive for CD44 and ALDH, confirming sLeX preferential expression in CSC. Furthermore, our analysis of sLex/CD44 co-expression has shown important overlap in our head and neck tumor cell lines, particularly in the metastatic ones. Of interest, sLeX1 tumor cells exhibit higher abilities in binding to the endothelium, in support of the sLeX involvement in critical steps of the metastatic process. Furthermore, our in vitro evaluation of the sLeX expression in HNSCC has indicated that among the various head and neck sites, sLeX expression was higher in oral-derived HNSCC, especially in those who developed metastasis or recurrences or have relapsed after failing standard treatment. These data are consistent with data generated in a parallel study in patient biopsies, where we found that sLeX expression was higher in oral and oropharynx carcinomas and associated with poor patient outcome (unpublished data). We are currently extending this analysis in our collections of tumor microarray generated from primary and metastatic oralderived carcinomas to further explore the clinical significance of sLeX as a reliable biomarker for metastatic potential in HNSCC. Our preliminary findings have indicated that sLeX expression correlates with lymph nodes metastasis (unpublished data); larger population-based studies are currently under investigation. Its potential predictive value for the clinical outcome and patient survival will be subsequently tested in our patient population.
The current study was designed to evaluate the expression profile of sLeX in relation with the CD44 status in CSC in HNSCC. Given the limitations of the present in vitro study, future studies focused on better understanding the clinical significance and biological functions of sLeX in CSC as it relates to HNSCC are needed. In addition, further purification of the stemlike cell population in HNSCC is necessary to clarify what metastatic characteristics are indeed unique to these cells; such evidence would allow clinicians to exploit this particular set of attributes to target cancer cells that keep a tumor growing and allow it to spread. The long-term aim of this series of experiments is to better characterize CSC in HNSCC as a first step in designing novel modalities to prevent HNSCC metastasis and thus, to improve patient outcome.
Conclusion
Taken together, our findings provide the first evidence of sLeX relationship with the CD44/ALDH status in CSC from head and neck carcinomas and extend our previous studies on the molecular characterization of CSC in HNSCC. The aim of these studies is to lay a foundation for the design of novel diagnostic and therapeutic approaches, resulting in improvement of HNSCC management and patient outcome.
